Preterm Birth and Biomarkers for Cardiovascular Disease

Study Overview
=================
Brief Summary
-----------------
Preterm birth is associated with maternal increased risk of cardiovascular disease later in life. In an observational case- control study, investigators want to evaluate whether women with preterm birth have increased levels of biomarkers for cardiovascular disease, to reveal potential pathophysiological mechanisms in common.

Detailed Description
-----------------
Women with spontaneous preterm birth in first pregnancy and a group of matched controls with spontaneous birth in normal time where invited to participate in the study. Participants were identified from the Biobank of Pregnant Women in Uppsala. Levels of cardiovascular biomarkers will be analyzed in plasma samples from the pregnancy and at a follow-up visit where investigators also collect information about other cardiovascular risk factors and lipid status.

Official Title
-----------------
Preterm Birth and Biomarkers for Cardiovascular Disease

Conditions
-----------------
Preterm Birth, Cardiovascular Diseases

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women identified as cases or controls Exclusion Criteria: System inflammatory disease Smoking at the time of the pregnancy

Ages Eligible for Study
-----------------
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Preterm birth<br>Women with spontaneous preterm birth in first pregnancy | Other: No intervention<br>* No intervention<br>|
| Controls<br>Matched controls with spontaneous delivery in normal time in first pregnancy | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of Factor XII in plasma in women with preterm birth in compared to a control group with delivery in normal time. | Levels of Factor XII in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of complement C5 in women with preterm birth in compared to a control group with delivery in normal time. | Levels of complement C5 in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of apolipoprotein M in women with preterm birth in compared to a control group with delivery in normal time. | Levels of apolipoprotein M in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of fibrinogen in women with preterm birth in compared to a control group with delivery in normal time. | Levels of fibrinogen in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of plasma kallikrein in women with preterm birth in compared to a control group with delivery in normal time. | Levels of plasma kallikrein in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of vitamin D binding protein in women with preterm birth in compared to a control group with delivery in normal time. | Levels of vitamin D binding protein in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of cadherin -5 in women with preterm birth in compared to a control group with delivery in normal time. | Levels of cadherin -5 in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 | 
| Levels of growth/differentiation Factor-15 (GDF-15) in women with preterm birth in compared to a control group with delivery in normal time. preterm birth compared to a control group with delivery in normal time. | Levels of growth/differentiation Factor-15 (GDF-15) in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected. | spring 2023 |